Compare PNW & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNW | BIO |
|---|---|---|
| Founded | 1985 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Laboratory Analytical Instruments |
| Sector | Utilities | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 8.2B |
| IPO Year | N/A | N/A |
| Metric | PNW | BIO |
|---|---|---|
| Price | $87.51 | $300.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $95.73 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 1.3M | 170.4K |
| Earning Date | 11-03-2025 | 10-29-2025 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.92 | N/A |
| Revenue | ★ $5,307,180,000.00 | $2,557,500,000.00 |
| Revenue This Year | $4.78 | $1.77 |
| Revenue Next Year | $4.15 | $2.30 |
| P/E Ratio | $17.75 | ★ N/A |
| Revenue Growth | ★ 5.70 | N/A |
| 52 Week Low | $81.47 | $211.43 |
| 52 Week High | $96.50 | $373.69 |
| Indicator | PNW | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 39.06 |
| Support Level | $87.36 | $298.02 |
| Resistance Level | $89.25 | $307.78 |
| Average True Range (ATR) | 1.17 | 8.35 |
| MACD | 0.06 | -2.13 |
| Stochastic Oscillator | 36.21 | 16.30 |
Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases 6.5 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.